Cardiovascular Drugs and Therapy

, Volume 27, Issue 2, pp 139–143

Chymase Inhibition and Cardiovascular Protection

REVIEW ARTICLE

DOI: 10.1007/s10557-013-6450-4

Cite this article as:
Tojo, H. & Urata, H. Cardiovasc Drugs Ther (2013) 27: 139. doi:10.1007/s10557-013-6450-4
  • 336 Downloads

Abstract

Human chymase, an angiotensin II-forming chymotrypsin-like serine proteinase, posses various biological actions mediating through local angiotensin II formation in the tissue level of many cardiovascular organs. Our previous experimental data have shown that chymase inhibitor increased a survival rate of the hamster post-myocardial infarction model with concomitant improvements of the cardiac function and hypertrophy, decreased hamster aortic atherosclerotic lesion induced by a high fat diet and improved hamster diabetic nephropathy decreasing the proteinuria and increased renal antiotensin II levels. Although chymase inhibitor has not yet been applied for clinical use, clinical cardiovascular diseases above mentioned appear to be the target of chymase inhibitor. The related basal and clinical circumstances are discussed in this review article for chymase inhibitor.

Keywords

angiotensin IIserine proteinaselocal renin-angiotensin system

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Cardiovascular DiseasesFukuoka University Chikushi HospitalChikushino-cityJapan